A citation-based method for searching scientific literature

Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley, Neil Davis, Ed Dicks, Rebecca Ewing, Yvonne Floyd, Kristian Gray, Sarah Hall, Rachel Hawes, Jaime Hughes, Vivian Kosmidou, Andrew Menzies, Catherine Mould, Adrian Parker, Claire Stevens, Stephen Watt, Steven Hooper, Rebecca Wilson, Hiran Jayatilake, Barry A Gusterson, Colin Cooper, Janet Shipley, Darren Hargrave, Katherine Pritchard-Jones, Norman Maitland, Georgia Chenevix-Trench, Gregory J Riggins, Darell D Bigner, Giuseppe Palmieri, Antonio Cossu, Adrienne Flanagan, Andrew Nicholson, Judy W C Ho, Suet Y Leung, Siu T Yuen, Barbara L Weber, Hilliard F Seigler, Timothy L Darrow, Hugh Paterson, Richard Marais, Christopher J Marshall, Richard Wooster, Michael R Stratton, P Andrew Futreal. Nature 2002
Times Cited: 7127







List of co-cited articles
670 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
16

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
14


Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean Jacques Grob,[...]. N Engl J Med 2014
14

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko,[...]. N Engl J Med 2019
334
14

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford,[...]. Cell 2004
14

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer,[...]. Lancet Oncol 2018
326
12

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, Victoria Atkinson, Gabrielle Liszkay, Anna Maria Di Giacomo, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. Lancet Oncol 2016
471
11

Improved overall survival in melanoma with combined dabrafenib and trametinib.
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier,[...]. N Engl J Med 2015
11

Inhibition of mutated, activated BRAF in metastatic melanoma.
Keith T Flaherty, Igor Puzanov, Kevin B Kim, Antoni Ribas, Grant A McArthur, Jeffrey A Sosman, Peter J O'Dwyer, Richard J Lee, Joseph F Grippo, Keith Nolop,[...]. N Engl J Med 2010
11

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
James Larkin, Paolo A Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. N Engl J Med 2014
11

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. N Engl J Med 2019
342
11

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
10

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
G V Long, K T Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, C Garbe, T Jouary, A Hauschild,[...]. Ann Oncol 2017
285
10

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean-Jacques Grob,[...]. Lancet 2015
771
9

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Keith T Flaherty, Jeffery R Infante, Adil Daud, Rene Gonzalez, Richard F Kefford, Jeffrey Sosman, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Nageatte Ibrahim,[...]. N Engl J Med 2012
9

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikos I Poulikakos, Chao Zhang, Gideon Bollag, Kevan M Shokat, Neal Rosen. Nature 2010
9

Distinct sets of genetic alterations in melanoma.
John A Curtin, Jane Fridlyand, Toshiro Kageshita, Hetal N Patel, Klaus J Busam, Heinz Kutzner, Kwang-Hyun Cho, Setsuya Aiba, Eva-Bettina Bröcker, Philip E LeBoit,[...]. N Engl J Med 2005
9

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
9

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
8

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
Dennie T Frederick, Adriano Piris, Alexandria P Cogdill, Zachary A Cooper, Cecilia Lezcano, Cristina R Ferrone, Devarati Mitra, Andrea Boni, Lindsay P Newton, Chengwen Liu,[...]. Clin Cancer Res 2013
614
8

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. N Engl J Med 2019
842
8

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
8

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, Erin M Coffee, Michiya Nishino, Alexandria P Cogdill, Ronald D Brown, Patricia Della Pelle, Dora Dias-Santagata, Kenneth E Hung,[...]. Cancer Discov 2012
586
8

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Anirudh Prahallad, Chong Sun, Sidong Huang, Federica Di Nicolantonio, Ramon Salazar, Davide Zecchin, Roderick L Beijersbergen, Alberto Bardelli, René Bernards. Nature 2012
8

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B Johnson, Kimberly B Dahlman,[...]. Cancer Discov 2014
630
8

Improved survival with MEK inhibition in BRAF-mutated melanoma.
Keith T Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev V Demidov, Jessica C Hassel, Piotr Rutkowski, Peter Mohr,[...]. N Engl J Med 2012
7

Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha,[...]. N Engl J Med 2015
7

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
7

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer,[...]. Lancet Oncol 2018
215
7

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Antoni Ribas, Donald Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H Miller, Matteo S Carlino, Rosalie Fisher, Georgina V Long, F Stephen Hodi, Jennifer Tsoi,[...]. Nat Med 2019
127
7

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent-Puig,[...]. Lancet Oncol 2010
7

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
Willy Hugo, Hubing Shi, Lu Sun, Marco Piva, Chunying Song, Xiangju Kong, Gatien Moriceau, Aayoung Hong, Kimberly B Dahlman, Douglas B Johnson,[...]. Cell 2015
327
7

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Scott Kopetz, Jayesh Desai, Emily Chan, Joel Randolph Hecht, Peter J O'Dwyer, Dipen Maru, Van Morris, Filip Janku, Arvind Dasari, Woonbook Chung,[...]. J Clin Oncol 2015
359
7

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
Alexander M Menzies, Lauren E Haydu, Lydia Visintin, Matteo S Carlino, Julie R Howle, John F Thompson, Richard F Kefford, Richard A Scolyer, Georgina V Long. Clin Cancer Res 2012
290
7

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Jeffrey A Sosman, Kevin B Kim, Lynn Schuchter, Rene Gonzalez, Anna C Pavlick, Jeffrey S Weber, Grant A McArthur, Thomas E Hutson, Stergios J Moschos, Keith T Flaherty,[...]. N Engl J Med 2012
7

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
7

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, Helen J Gogas, Ana M Arance, C Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion-Sileni, Ivan Marquez-Rodas,[...]. N Engl J Med 2017
975
6

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V Long, Anna Maria Di Giacomo,[...]. Nat Med 2019
117
6

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
Grant A McArthur, Paul B Chapman, Caroline Robert, James Larkin, John B Haanen, Reinhard Dummer, Antoni Ribas, David Hogg, Omid Hamid, Paolo A Ascierto,[...]. Lancet Oncol 2014
653
6

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Eliezer M Van Allen, Nikhil Wagle, Antje Sucker, Daniel J Treacy, Cory M Johannessen, Eva M Goetz, Chelsea S Place, Amaro Taylor-Weiner, Steven Whittaker, Gregory V Kryukov,[...]. Cancer Discov 2014
573
6

Melanoma.
Dirk Schadendorf, Alexander C J van Akkooi, Carola Berking, Klaus G Griewank, Ralf Gutzmer, Axel Hauschild, Andreas Stang, Alexander Roesch, Selma Ugurel. Lancet 2018
348
6

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Georgina V Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon,[...]. N Engl J Med 2017
641
6

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, Vernon K Sondak, Georgina V Long, Merrick I Ross, Alexander J Lazar, Mark B Faries, John M Kirkwood, Grant A McArthur,[...]. CA Cancer J Clin 2017
839
6

A landscape of driver mutations in melanoma.
Eran Hodis, Ian R Watson, Gregory V Kryukov, Stefan T Arold, Marcin Imielinski, Jean-Philippe Theurillat, Elizabeth Nickerson, Daniel Auclair, Liren Li, Chelsea Place,[...]. Cell 2012
6

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Sonja J Heidorn, Carla Milagre, Steven Whittaker, Arnaud Nourry, Ion Niculescu-Duvas, Nathalie Dhomen, Jahan Hussain, Jorge S Reis-Filho, Caroline J Springer, Catrin Pritchard,[...]. Cell 2010
6

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Georgia Hatzivassiliou, Kyung Song, Ivana Yen, Barbara J Brandhuber, Daniel J Anderson, Ryan Alvarado, Mary J C Ludlam, David Stokoe, Susan L Gloor, Guy Vigers,[...]. Nature 2010
6

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, Cristiana Lupi, Elisa Sensi, Sara Lonardi, Silvia Mezi, Gianluca Tomasello, Monica Ronzoni, Alberto Zaniboni,[...]. Lancet Oncol 2015
471
6

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
981
6

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem,[...]. N Engl J Med 2013
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.